Novo Nordisk A/S (NYSE:NVO) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.
A number of other research analysts also recently commented on NVO. Zacks Investment Research downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Wednesday, April 19th. TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a report on Tuesday, May 2nd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company. Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $53.00.
Novo Nordisk A/S (NYSE:NVO) opened at 45.81 on Friday. Novo Nordisk A/S has a 52-week low of $30.89 and a 52-week high of $47.98. The firm’s 50-day moving average price is $42.76 and its 200 day moving average price is $38.81. The firm has a market cap of $113.68 billion, a price-to-earnings ratio of 18.74 and a beta of 0.63.
ILLEGAL ACTIVITY WARNING: “Novo Nordisk A/S (NVO) Raised to Hold at BidaskClub” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/08/12/novo-nordisk-as-nvo-raised-to-hold-at-bidaskclub.html.
Several hedge funds have recently made changes to their positions in the company. Proficio Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock valued at $103,000 after buying an additional 1,505 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock valued at $105,000 after buying an additional 1,918 shares during the period. AlphaMark Advisors LLC increased its stake in shares of Novo Nordisk A/S by 1.1% in the second quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock valued at $113,000 after buying an additional 30 shares during the period. Parallel Advisors LLC increased its stake in shares of Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock valued at $117,000 after buying an additional 1,553 shares during the period. Finally, Advisory Services Network LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $127,000. 6.40% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
What are top analysts saying about Novo Nordisk A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novo Nordisk A/S and related companies.